-
A Potential Breakthrough in Oral Cancer: PRV-111 and the Shift Toward Non-Surgical Treatment
The Search for Alternatives in Oral Cancer Care For patients diagnosed with early-stage oral cancer, surgery has long been the standard of care. While effective, surgery in the oral cavity can often result in significant functional and aesthetic challenges. Recently, Provention Bio, Inc., a subsidiary of Sanofi, provided a clinical update on their ongoing Phase…
-
Sanofi’s $2.2 Billion Bet: What Their Acquisition of an HBV Vaccine Maker Means for Global Health
NASDAQ: $SNY In a move that sent ripples through the pharmaceutical landscape, Sanofi recently announced its acquisition of a Hepatitis B (HBV) vaccine maker for a staggering $2.2 billion. This strategic purchase, detailed in a recent article from Pharmaceutical Technology, isn’t just a financial transaction; it represents a significant investment in global public health and…